Eli Lilly’s Sales Slash… And How To Position Ahead Of Bank Results 1/14/25

CNBC's "Fast Money"

CNBC

Business, Investing, News

4.3 • 1.2K Ratings

🗓️ 14 January 2025

⏱️ 44 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Shares of Eli Lilly taking a hit, as the pharma giant cuts its sales outlook. But could the dip be a buying opportunity? The latest out of JP Morgan’s Health Care Conference in San Francisco. And speaking of JP Morgan… the big bank and its peers kicking off earnings season tomorrow. What to expect from those results and why one top bank analyst says it’s all about the yield curve for the group. Fast Money Disclaimer

Transcript

Click on a timestamp to play from that location

0:00.0	Live from the Nazak market site in the heart of New York City's Times Square, this is fast money.
0:07.4	Here's what's on tap tonight.
0:08.9	Losing weight.
0:09.7	Shares of the ones red-hot Eli Lilly seen their worst day since 2021.
0:14.3	If the air can even come out of this trade, what's the mean for the other big winner of last year, AI?
0:19.9	And a social reckoning.
0:21.1	We may be on the verge of a TikTok shutdown in the U.S.,
0:23.6	but that doesn't seem to be helping its competitors.
0:25.7	We dive into the details coming up.
0:27.7	Plus, big banks getting ready to report
0:29.3	with J.P. Morgan Goldman Sachs and more on deck tomorrow.
0:32.5	Quantum computing stocks leap higher after a recent sell-off
0:35.3	and the reveal of two more trader acronyms.
0:38.0	One of our traders came out with not just their picks, but a full definition.
0:42.2	We'll let you guess who that was.
0:44.0	I'm Melissa Leak.
0:44.7	I'm with you live from Studio Bia at the Nazak on the desk tonight.
0:47.1	Steve Ross out, Dan Nathan, Guy Adami, and Julie Beale.
0:49.8	We start off with the big GLP1 drug maker drop, Eli Lilly, sinking 6.5% for its worst day since March 2021, shedding about $50 billion in market cap.
1:00.9	The move coming after the company gave a disappointing Q4 revenue outlook with sales of its blockbuster drugs, Zepbound and Manjaro, growing slower than expected.
1:09.1	The news also taking a bite out of rival Novo Nordisk
1:11.4	down 4% today. That stock now trading at August 2023 lows. It's lost nearly half of its value
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from CNBC, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of CNBC and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.